Diffusion Pharmaceuticals Performance
| DFFNDelisted Stock | USD 3.27 0.17 5.48% |
The firm shows a Beta (market volatility) of 0.3, which means possible diversification benefits within a given portfolio. As returns on the market increase, Diffusion Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Diffusion Pharmaceuticals is expected to be smaller as well. Diffusion Pharmaceuticals right now shows a risk of 0.0%. Please confirm Diffusion Pharmaceuticals potential upside, and the relationship between the total risk alpha and daily balance of power , to decide if Diffusion Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Diffusion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Diffusion Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 37.3 M |
Diffusion |
Diffusion Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 327.00 in Diffusion Pharmaceuticals on September 19, 2024 and sell it today you would earn a total of 0.00 from holding Diffusion Pharmaceuticals or generate 0.0% return on investment over 90 days. Diffusion Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Diffusion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Diffusion Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diffusion Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diffusion Pharmaceuticals, and traders can use it to determine the average amount a Diffusion Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| DFFN |
Based on monthly moving average Diffusion Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diffusion Pharmaceuticals by adding Diffusion Pharmaceuticals to a well-diversified portfolio.
Diffusion Pharmaceuticals Fundamentals Growth
Diffusion Stock prices reflect investors' perceptions of the future prospects and financial health of Diffusion Pharmaceuticals, and Diffusion Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diffusion Stock performance.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | (6.02 M) | |||
| Shares Outstanding | 2.04 M | |||
| Price To Earning | (0.60) X | |||
| Price To Book | 0.51 X | |||
| EBITDA | (15.97 M) | |||
| Cash And Equivalents | 25.86 M | |||
| Cash Per Share | 12.68 X | |||
| Total Debt | 67.89 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 6.97 X | |||
| Cash Flow From Operations | (14.97 M) | |||
| Earnings Per Share | (7.11) X | |||
| Total Asset | 22.64 M | |||
| Retained Earnings | (145.6 M) | |||
| Current Asset | 3.29 M | |||
| Current Liabilities | 3.68 M | |||
About Diffusion Pharmaceuticals Performance
By examining Diffusion Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Diffusion Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Diffusion Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the bodys ability to deliver oxygen. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia. Diffusion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Things to note about Diffusion Pharmaceuticals performance evaluation
Checking the ongoing alerts about Diffusion Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diffusion Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diffusion Pharmaceuticals is not yet fully synchronised with the market data | |
| Diffusion Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (15.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Diffusion Pharmaceuticals currently holds about 25.86 M in cash with (14.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Diffusion Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diffusion Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Diffusion Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diffusion Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diffusion Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diffusion Pharmaceuticals' stock. These opinions can provide insight into Diffusion Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Diffusion Stock
If you are still planning to invest in Diffusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Diffusion Pharmaceuticals' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance |